Gumbo Education Nurse Practitioners CEUs Podcast
Episode 25 - Pathway-Driven Management of Inflammatory Bowel Disease
Pathway-Driven Management of Inflammatory Bowel Disease
The article is worth 1 contact hour of continuing education all of which is towards pharmacology.
by: Deborah L. Dillon, DNP, ACNP-BC and Jessica E. Crimaldi, MSN, CNP
- Published:June 24, 2020
- DOI:https://doi.org/10.1016/j.nurpra.2020.04.020
UC is a gastrointestinal (GI) disease that is localized to the large intestine, or colon, where inflammation can affect either the entire organ or a portion of it. Approximately 1.86 billion patients have been diagnosed with UC globally, with 1.54 billion patients currently receiving treatment. Traditional therapies have yielded $4.18 billion in annual sales around the world, a figure expected to increase to $6.85 billion by 2022 with the approval of various pipeline drugs (Gohil and Carramusa, 2014).
CD can affect any part of the GI tract, but most commonly involves both the large and small intestines. Although CD is more severe than UC, the global prevalence is much lower, with only 1.3 million patients diagnosed and 0.8 million who currently receive treatment. Still, traditional therapies have resulted in an impressive $3.17 billion in global market sales, which is predicted to increase to $4.20 billion by 2022 (Gohil and Carramusa, 2014).
Traditional therapies are highly effective in these hard-to-treat diseases. Tumor necrosis factor (TNF) inhibitors are firmly established as treatments but sometimes present problems, such as immunogenicity or an eventual loss of response (Gohil and Carramusa, 2014).
Gohil, K., & Carramusa, B. (2014). Ulcerative colitis and Crohn's disease. P & T : a peer-reviewed journal for formulary management, 39(8), 576–577.
Everyone can purchase from http://gumboeducation.com/casey-and-the-crawfish
Or try the Kindle Edition from Amazon https://www.amazon.com/dp/B08DLB473N
BULLYING PREVENTION FOR NURSES - A REAL SOLUTION: CONTACT HOURS WILL BE AWARDED: